Calamos Advisors’s NxStage Medical Inc. NXTM Stock Holding History

Calamos Advisors’s Portfolio NXTM Stock Details NXTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-21,550	Closed	-$323K	–	656
2016 Q1	$323K	Sell	21,550 -3,650	-14%	-$61.2K	﹤0.01%	581
2015 Q4	$552K	Sell	25,200 -7,500	-23%	-$140K	﹤0.01%	570
2015 Q3	$516K	Buy	32,700 +15,000	+85%	+$240K	﹤0.01%	595
2015 Q2	$253K	Sell	17,700 -212,632	-92%	-$3.6M	﹤0.01%	634
2015 Q1	$3.98M	Hold	230,332	–	–	0.03%	404
2014 Q4	$4.13M	Buy	+230,332	New	+$3.71M	0.03%	375

Other funds holding NXTM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Calamos Advisors's NXTM Position: Q2 2016 in Review

Calamos Advisors sold out of NxStage Medical Inc. (NXTM) in Q2 2016, closing a stake of 21,550 shares — an estimated $323K sold.

Calamos Advisors first reported a position in NXTM in Q4 2014 and held it in 6 quarters. The position peaked at $4.13M in Q4 2014. 147 funds tracked by Wall St. Rank hold NXTM as of Q2 2016.

Calamos Advisors reported no remaining NxStage Medical Inc. position as of Q2 2016 after selling out during the quarter.
Calamos Advisors sold 21,550 NxStage Medical Inc. shares in Q2 2016, an estimated $323K.
Calamos Advisors first reported a position in NxStage Medical Inc. in Q4 2014 and held it in 6 quarters.
Calamos Advisors's NxStage Medical Inc. position peaked at $4.13M in Q4 2014.
147 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q2 2016.

Based on Calamos Advisors's 13F filing for Q2 2016, filed 26 Jul 2016.